CLDX (Celldex Therapeutics Inc) dropped -4.33 at the last close: Is This Today’s Most Popular Stock?

Celldex Therapeutics Inc (NASDAQ: CLDX) kicked off on Monday, down -4.33% from the previous trading day, before settling in for the closing price of $21.26. Over the past 52 weeks, CLDX has traded in a range of $14.40-$47.00.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

During the last 5-year period, the sales growth of Healthcare Sector giant was 14.46%. While this was happening, its average annual earnings per share was recorded -40.83%. With a float of $64.51 million, this company’s outstanding shares have now reached $66.38 million.

Let’s determine the extent of company efficiency that accounts for 186 employees. In terms of profitability, gross margin is 78.62%, operating margin of -2873.52%, and the pretax margin is -2366.07%.

Celldex Therapeutics Inc (CLDX) Breakdown of a Key Holders of the stock

Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Celldex Therapeutics Inc is 2.84%, while institutional ownership is 109.39%. The most recent insider transaction that took place on Nov 11 ’24, was worth 308,430. In this transaction PRESIDENT & CEO of this company bought 11,500 shares at a rate of $26.82, taking the stock ownership to the 40,284 shares.

Celldex Therapeutics Inc (CLDX) Recent Fiscal highlights

According to the Wall Street analysts, stocks earnings will be around -40.83% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -16.47% during the next five years compared to 6.91% growth over the previous five years of trading.

Celldex Therapeutics Inc (NASDAQ: CLDX) Trading Performance Indicators

Take a look at Celldex Therapeutics Inc’s (CLDX) current performance indicators. Last quarter, stock had a quick ratio of 21.67. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 178.63.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.70, a number that is poised to hit -0.86 in the next quarter and is forecasted to reach -4.02 in one year’s time.

Technical Analysis of Celldex Therapeutics Inc (CLDX)

Looking closely at Celldex Therapeutics Inc (NASDAQ: CLDX), its last 5-days average volume was 1.64 million, which is a jump from its year-to-date volume of 0.92 million. As of the previous 9 days, the stock’s Stochastic %D was 35.91%. Additionally, its Average True Range was 1.43.

During the past 100 days, Celldex Therapeutics Inc’s (CLDX) raw stochastic average was set at 50.08%, which indicates a significant increase from 32.66% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 61.20% in the past 14 days, which was higher than the 60.43% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $19.38, while its 200-day Moving Average is $25.15. However, in the short run, Celldex Therapeutics Inc’s stock first resistance to watch stands at $21.22. Second resistance stands at $22.11. The third major resistance level sits at $22.78. If the price goes on to break the first support level at $19.66, it is likely to go to the next support level at $18.99. Now, if the price goes above the second support level, the third support stands at $18.10.

Celldex Therapeutics Inc (NASDAQ: CLDX) Key Stats

The company with the Market Capitalisation of 1.35 billion has total of 66,384K Shares Outstanding. Its annual sales at the moment are 7,020 K in contrast with the sum of -157,860 K annual income. Company’s last quarter sales were recorded 700 K and last quarter income was -53,800 K.

News Daemon
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.